drugset / Trial / NCT07219030
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
RandomizedSequentialQuadruple-blindBasic science
Summary
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
Timeline
- Start
- 2025-10-08
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Emraclidine | Small molecule | — | Oral |
Indications
No indication recorded.